Navigation Links
Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
Date:7/20/2009

g previous results, or not achieving the intended clinical endpoints; the DURATION-3 superiority study results potentially not being predictive of real world use including results relative to other diabetes medications; pre-clinical trials not predicting future results; label expansion requests or New Drug Application (NDA) filings, not being submitted in a timely manner; regulatory approval, including approval for exenatide once weekly, being delayed or not received; or manufacturing and supply issues. The potential for exenatide once weekly may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the development and commercialization of pharmaceutical products including those inherent in the collaboration with and dependence upon Amylin, Lilly and/or Alkermes. These and additional risks and uncertainties are described more fully in Amylin's, Lilly's and Alkermes' most recent SEC filings including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Amylin, Lilly and Alkermes undertake no duty to update these forward-looking statements.

P-LLY

(i) "All About Diabetes." American Diabetes Association. Available at:http://www.diabetes.org/about-diabetes.jsp. Accessed July 13, 2009.

(ii) The International Diabetes Federation Diabetes Atlas. Available at:http://www.idf.org/home/index.cfm?unode=3B96906B-C026-2FD3-87B73F80BC22682A. Accessed July 13, 2009.

(iii) "Direct and Indirect Costs of Diabetes in the United States." American Diabetes Association. Available at:http://www.diabetes.org/diabe
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
2. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
3. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
4. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
5. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
6. Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
7. Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
8. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
9. Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
10. Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
11. The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014  ConvaTec, a privately-held medical products and technologies ... been appointed chief financial officer of the company, effective ... executive vice president and chief financial officer of Elan ... Mr. Clerkin was part of a senior team that ... its sale to Perrigo, a pharmaceutical manufacturer, in December ...
(Date:7/22/2014)... , July 22, 2014  According to the American ... children spend on digital devices. An AOA survey reports ... 10 and 17 estimate they use an electronic device ... separate AOA survey of parents revealed that only 40 ... device for that same amount of time. Eye doctors ...
(Date:7/22/2014)... , July 22, 2014  NeuroSigma, Inc. (NeuroSigma), ... focused on commercialization of its non-invasive Monarch ... and neuropsychiatric disorders, today announced that enrollment has begun ... nerve stimulation (eTNS) as adjunctive therapy for the treatment ... being conducted at the Olive View-UCLA Medical Center in ...
Breaking Medicine Technology:ConvaTec Names Nigel Clerkin Chief Financial Officer 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5
... Infection Prevention Professionals With Guidelines,and Tools, ... Association for,Professionals in Infection Control and ... new educational initiatives aimed at eliminating,healthcare-associated ... and the three infections that the ...
... Innocoll, Inc., a privately-held,specialty pharmaceutical company, announced ... clinical trials sponsored by its wholly owned ... TOPICAL for the,treatment and prevention of infected ... GENTAMICIN TOPICAL is a biodegradable and fully ...
Cached Medicine Technology:APIC Launches 'Targeting Zero' Initiative to Eradicate C. Difficile and Infections Deemed Preventable By CMS 2APIC Launches 'Targeting Zero' Initiative to Eradicate C. Difficile and Infections Deemed Preventable By CMS 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 4
(Date:7/22/2014)... July 22, 2014 (HealthDay News) -- Genetic fragments of the ... barn where an infected camel was kept, a new study ... to determine if Middle East Respiratory Syndrome (MERS) can be ... air samples over three consecutive days from a camel barn ... of the town of Jeddah, Saudi Arabia. The man later ...
(Date:7/22/2014)... electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS), ... Like antidepressant medications, however, they typically have a ... several weeks of regular ECT treatments before a ... an impetus to develop antidepressant treatments that act ... (LFMS) is one such potential new treatment with ...
(Date:7/22/2014)... The “Human Insulin Market by Product ... Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], ... Others) - Forecast to 2019” provides a detailed ... current market trends, and strategies impacting the global ... forecasts of the revenue and share analysis. , ...
(Date:7/22/2014)... Cloud+MD Office 2.0 is a ... medical software and services, designed by experienced healthcare ... “Actionable Information” to help Independent Physician Practices, New ... Services optimize a wide range of business processes ... Noticeable Cost Reductions and Better Patient Care. ...
(Date:7/22/2014)... 2014 For the past nine years, ... been working in tandem to help thousands of cancer ... to care, and help survivors connect to resources dealing ... expanded their partnership to include referrals from PAF to ... the other practical, emotional, and financial issues that accompany ...
Breaking Medicine News(10 mins):Health News:MERS Virus Found in Air in Camel Barn 2Health News:Low strength brain stimulation may be effective for depression 2Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 5Health News:Cloud-MD Software will soon Receive MU2 Certification 2Health News:LIVESTRONG Foundation and Patient Advocate Foundation Expand Partnership to Support the Needs of Cancer Patients and Survivors Nationwide 2Health News:LIVESTRONG Foundation and Patient Advocate Foundation Expand Partnership to Support the Needs of Cancer Patients and Survivors Nationwide 3
... and NEW YORK, Feb. 11 ActivCore ... exclusive distributor of Redcord,products in the United ... with,Wellness in Motion (WIM). ActivCore will ... Training Network that will serve,therapy professionals, chiropractors, ...
... to Make Women,s Concerns Central to National Health ... Stabenow (D-MI), House Democratic Co-Chair of the Congressional ... other Congressional leaders introduced a resolution today that ... will make women,s needs a key part of ...
... announces FDA 510(k) Class,II clearance for the world,s ... respiration rates, bed occupancy and,movement. Under the brand ... device in the US and Canada under an ... 2000 received the sign off from,the FDA,s Division ...
... Demonstrates That Small Gains in Member Retention ... Market research conducted on behalf of ... can significantly improve revenue generation by establishing ... host of economic factors are currently driving ...
... (NYSE: HRC ) invites you to listen ... Investor Relations, Communications and Global Brand,Development, Hill-Rom. He ... in Las Vegas on Tuesday, February 24, 2009, at,9:40 ... invited to listen to the live audio-only webcast via ...
... through Associate Giving CampaignDENVER, Feb. 11 Anthem ... a long history of giving back to the ... 2008, the strong commitment continued through financial support ... Foundation and the generosity of the company,s associates.Anthem,s ...
Cached Medicine News:Health News:ActivCore LLC Announces Strategic Partnership with Wellness in Motion 2Health News:Congressional Leaders, Public Health Experts Announce New Framework to Promote Women's Health 2Health News:Congressional Leaders, Public Health Experts Announce New Framework to Promote Women's Health 3Health News:Sensiotec Announces FDA 510(k) Class II Clearance for the World's First UWB Healthcare Unbound, Wireless, Non-Contact, Vital Signs and Movement Monitor 2Health News:Lowering Health Insurance Member Disenrollment Can Generate up to $100 Million in Incremental Revenue for Health Plans 2Health News:Lowering Health Insurance Member Disenrollment Can Generate up to $100 Million in Incremental Revenue for Health Plans 3Health News:Anthem Blue Cross and Blue Shield in Colorado and its Foundation Commit $1.6 Million in 2008 2Health News:Anthem Blue Cross and Blue Shield in Colorado and its Foundation Commit $1.6 Million in 2008 3Health News:Anthem Blue Cross and Blue Shield in Colorado and its Foundation Commit $1.6 Million in 2008 4
Dnase-free, with an integral filter to protect against carry over and contamination from aerosols...
... TowerPack is an innovative, quick and ... Tips. Use 60% less space on ... plastic. With this amazingly easy-to-use, one-hand ... for the whole range of Diamond ...
300 L, Racked, 96 tips/rack Recommended for 250 and 300 L pipettes. Can also be used with 20, 25, 50, 100 and 200 L pipette...
... to optimize the accuracy and precision of ... is widely recognized by customers throughout the ... over the years and now covers a ... including filter tips, certified pure tips, stepper ...
Medicine Products: